Silence Therapeutics plc (LON:SLN)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $115.99 and traded as low as $184.00. Silence Therapeutics shares last traded at $187.00, with a volume of 20,220 shares changing hands.
Separately, Peel Hunt reaffirmed a “buy” rating on shares of Silence Therapeutics in a research report on Tuesday, September 24th.
The business’s 50 day simple moving average is GBX 197.22 and its 200-day simple moving average is GBX 115.99. The stock has a market capitalization of $147.25 million and a price-to-earnings ratio of -7.43.
In other news, insider Steven Romano bought 10,000 shares of Silence Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average cost of GBX 193 ($2.52) per share, with a total value of £19,300 ($25,218.87). Also, insider Dave Lemus bought 4,000 shares of Silence Therapeutics stock in a transaction on Friday, October 4th. The shares were purchased at an average cost of GBX 186 ($2.43) per share, with a total value of £7,440 ($9,721.68).
About Silence Therapeutics (LON:SLN)
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Read More: What defines an oversold asset?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.